Physician profile
Jenny Warwick
NPI 1427429323
$3,934.98
in general payments reported to CMS, 2019-2025
17 companies · $554 in 2025
The $554 reported for 2025 was more than what 80% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $575 · 2020: $274 · 2021: $106 · 2022: $784 · 2023: $681 · 2024: $962 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,152 · Entertainment: $44.31.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,152.06 |
| Entertainment | $44.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $1,040.86 | 2022-2025 | Infuse, Biotrue, Miebo |
| Alcon Vision LLC | $1,029.96 | 2019-2025 | Precision 1, Precision7, Total30 |
| Coopervision INC. | $456.49 | 2019-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $355.45 | 2019-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $192.25 | 2019-2020 | |
| Oyster Point Pharma, INC. | $180.92 | 2022-2024 | Tyrvaya |
| Johnson & Johnson Surgical Vision, INC. | $147.04 | 2022 | |
| Allergan, INC. | $113.49 | 2019-2022 | |
| Tarsus Pharmaceuticals, INC. | $87.92 | 2024-2025 | Xdemvy |
| Dompe US, INC. | $84.22 | 2024 | Oxervate |
| Optos, INC. | $82.17 | 2019-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Johnson & Johnson Vision Care, INC. | $41.14 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $37.79 | 2019-2020 | |
| Thea Pharma INC. | $32.70 | 2023 | |
| Kala Pharmaceuticals, INC. | $18.97 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18.81 | 2022 | |
| Shire North American Group INC | $14.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Warwick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.